667 related articles for article (PubMed ID: 33328650)
1. Genomic and phenotypic heterogeneity in prostate cancer.
Haffner MC; Zwart W; Roudier MP; True LD; Nelson WG; Epstein JI; De Marzo AM; Nelson PS; Yegnasubramanian S
Nat Rev Urol; 2021 Feb; 18(2):79-92. PubMed ID: 33328650
[TBL] [Abstract][Full Text] [Related]
2. Multifocal Primary Prostate Cancer Exhibits High Degree of Genomic Heterogeneity.
Løvf M; Zhao S; Axcrona U; Johannessen B; Bakken AC; Carm KT; Hoff AM; Myklebost O; Meza-Zepeda LA; Lie AK; Axcrona K; Lothe RA; Skotheim RI
Eur Urol; 2019 Mar; 75(3):498-505. PubMed ID: 30181068
[TBL] [Abstract][Full Text] [Related]
3. RB1 Heterogeneity in Advanced Metastatic Castration-Resistant Prostate Cancer.
Nava Rodrigues D; Casiraghi N; Romanel A; Crespo M; Miranda S; Rescigno P; Figueiredo I; Riisnaes R; Carreira S; Sumanasuriya S; Gasperini P; Sharp A; Mateo J; Makay A; McNair C; Schiewer M; Knudsen K; Boysen G; Demichelis F; de Bono JS
Clin Cancer Res; 2019 Jan; 25(2):687-697. PubMed ID: 30257982
[TBL] [Abstract][Full Text] [Related]
4. Exome sequencing of prostate cancer supports the hypothesis of independent tumour origins.
Lindberg J; Klevebring D; Liu W; Neiman M; Xu J; Wiklund P; Wiklund F; Mills IG; Egevad L; Grönberg H
Eur Urol; 2013 Feb; 63(2):347-53. PubMed ID: 22502944
[TBL] [Abstract][Full Text] [Related]
5. Comparative genomics of primary prostate cancer and paired metastases: insights from 12 molecular case studies.
Cyrta J; Prandi D; Arora A; Hovelson DH; Sboner A; Rodriguez A; Fedrizzi T; Beltran H; Robinson DR; Gopalan A; True L; Nelson PS; Robinson BD; Mosquera JM; Tomlins SA; Shen R; Demichelis F; Rubin MA
J Pathol; 2022 Jul; 257(3):274-284. PubMed ID: 35220606
[TBL] [Abstract][Full Text] [Related]
6. Genomic Heterogeneity Within Individual Prostate Cancer Foci Impacts Predictive Biomarkers of Targeted Therapy.
VanderWeele DJ; Finney R; Katayama K; Gillard M; Paner G; Imoto S; Yamaguchi R; Wheeler D; Lack J; Cam M; Pontier A; Nguyen YTM; Maejima K; Sasaki-Oku A; Nakano K; Tanaka H; Vander Griend D; Kubo M; Ratain MJ; Miyano S; Nakagawa H
Eur Urol Focus; 2019 May; 5(3):416-424. PubMed ID: 29398457
[TBL] [Abstract][Full Text] [Related]
7. Molecular Subtypes of Prostate Cancer.
Arora K; Barbieri CE
Curr Oncol Rep; 2018 Jun; 20(8):58. PubMed ID: 29858674
[TBL] [Abstract][Full Text] [Related]
8. Genomic, pathological, and clinical heterogeneity as drivers of personalized medicine in prostate cancer.
Fraser M; Berlin A; Bristow RG; van der Kwast T
Urol Oncol; 2015 Feb; 33(2):85-94. PubMed ID: 24768356
[TBL] [Abstract][Full Text] [Related]
9. Intratumoral and Intertumoral Genomic Heterogeneity of Multifocal Localized Prostate Cancer Impacts Molecular Classifications and Genomic Prognosticators.
Wei L; Wang J; Lampert E; Schlanger S; DePriest AD; Hu Q; Gomez EC; Murakam M; Glenn ST; Conroy J; Morrison C; Azabdaftari G; Mohler JL; Liu S; Heemers HV
Eur Urol; 2017 Feb; 71(2):183-192. PubMed ID: 27451135
[TBL] [Abstract][Full Text] [Related]
10. Genomic hallmarks of localized, non-indolent prostate cancer.
Fraser M; Sabelnykova VY; Yamaguchi TN; Heisler LE; Livingstone J; Huang V; Shiah YJ; Yousif F; Lin X; Masella AP; Fox NS; Xie M; Prokopec SD; Berlin A; Lalonde E; Ahmed M; Trudel D; Luo X; Beck TA; Meng A; Zhang J; D'Costa A; Denroche RE; Kong H; Espiritu SM; Chua ML; Wong A; Chong T; Sam M; Johns J; Timms L; Buchner NB; Orain M; Picard V; Hovington H; Murison A; Kron K; Harding NJ; P'ng C; Houlahan KE; Chu KC; Lo B; Nguyen F; Li CH; Sun RX; de Borja R; Cooper CI; Hopkins JF; Govind SK; Fung C; Waggott D; Green J; Haider S; Chan-Seng-Yue MA; Jung E; Wang Z; Bergeron A; Dal Pra A; Lacombe L; Collins CC; Sahinalp C; Lupien M; Fleshner NE; He HH; Fradet Y; Tetu B; van der Kwast T; McPherson JD; Bristow RG; Boutros PC
Nature; 2017 Jan; 541(7637):359-364. PubMed ID: 28068672
[TBL] [Abstract][Full Text] [Related]
11. The aging prostate is never "normal": implications from the genomic characterization of multifocal prostate cancers.
Schlomm T; Weischenfeldt J; Korbel J; Sauter G
Eur Urol; 2015 Sep; 68(3):348-50. PubMed ID: 25913065
[TBL] [Abstract][Full Text] [Related]
12. Clinical variability and molecular heterogeneity in prostate cancer.
Shoag J; Barbieri CE
Asian J Androl; 2016; 18(4):543-8. PubMed ID: 27080479
[TBL] [Abstract][Full Text] [Related]
13. Spatial Intratumor Genomic Heterogeneity within Localized Prostate Cancer Revealed by Single-nucleus Sequencing.
Su F; Zhang W; Zhang D; Zhang Y; Pang C; Huang Y; Wang M; Cui L; He L; Zhang J; Zou L; Zhang J; Li W; Li L; Shao J; Ma J; Xiao F; Liu M
Eur Urol; 2018 Nov; 74(5):551-559. PubMed ID: 29941308
[TBL] [Abstract][Full Text] [Related]
14. DNA methylation alterations exhibit intraindividual stability and interindividual heterogeneity in prostate cancer metastases.
Aryee MJ; Liu W; Engelmann JC; Nuhn P; Gurel M; Haffner MC; Esopi D; Irizarry RA; Getzenberg RH; Nelson WG; Luo J; Xu J; Isaacs WB; Bova GS; Yegnasubramanian S
Sci Transl Med; 2013 Jan; 5(169):169ra10. PubMed ID: 23345608
[TBL] [Abstract][Full Text] [Related]
15. Somatic alterations detected in diagnostic prostate biopsies provide an inadequate representation of multifocal prostate cancer.
Kristiansen A; Bergström R; Delahunt B; Samaratunga H; Guðjónsdóttir J; Grönberg H; Egevad L; Lindberg J
Prostate; 2019 Jun; 79(8):920-928. PubMed ID: 30908670
[TBL] [Abstract][Full Text] [Related]
16. Copy number analysis indicates monoclonal origin of lethal metastatic prostate cancer.
Liu W; Laitinen S; Khan S; Vihinen M; Kowalski J; Yu G; Chen L; Ewing CM; Eisenberger MA; Carducci MA; Nelson WG; Yegnasubramanian S; Luo J; Wang Y; Xu J; Isaacs WB; Visakorpi T; Bova GS
Nat Med; 2009 May; 15(5):559-65. PubMed ID: 19363497
[TBL] [Abstract][Full Text] [Related]
17. Prostate cancer research: The next generation; report from the 2019 Coffey-Holden Prostate Cancer Academy Meeting.
Miyahira AK; Sharp A; Ellis L; Jones J; Kaochar S; Larman HB; Quigley DA; Ye H; Simons JW; Pienta KJ; Soule HR
Prostate; 2020 Feb; 80(2):113-132. PubMed ID: 31825540
[TBL] [Abstract][Full Text] [Related]
18. Beyond the androgen receptor II: New approaches to understanding and treating metastatic prostate cancer; Report from the 2017 Coffey-Holden Prostate Cancer Academy Meeting.
Miyahira AK; Cheng HH; Abida W; Ellis L; Harshman LC; Spratt DE; Simons JW; Pienta KJ; Soule HR
Prostate; 2017 Nov; 77(15):1478-1488. PubMed ID: 28925066
[TBL] [Abstract][Full Text] [Related]
19. Intratumour heterogeneity in urologic cancers: from molecular evidence to clinical implications.
Gerlinger M; Catto JW; Orntoft TF; Real FX; Zwarthoff EC; Swanton C
Eur Urol; 2015 Apr; 67(4):729-37. PubMed ID: 24836153
[TBL] [Abstract][Full Text] [Related]
20. A three-marker FISH panel detects more genetic aberrations of AR, PTEN and TMPRSS2/ERG in castration-resistant or metastatic prostate cancers than in primary prostate tumors.
Qu X; Randhawa G; Friedman C; Kurland BF; Glaskova L; Coleman I; Mostaghel E; Higano CS; Porter C; Vessella R; Nelson PS; Fang M
PLoS One; 2013; 8(9):e74671. PubMed ID: 24098661
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
